-
Regulatory Intelligence & Drug Approvals1 month agoIgA nephropathy’s formula for continuous innovation
BIOCENTURY | PRODUCT DEVELOPMENTIGA NEPHROPATHY’S FORMULA FOR CONTINUOUS INNOVATIONSeven drugs have been approved for IgAN, but development continues for best-in-class products
-
Capital, M&A & Industry Strategy1 month agoMore IPO hopefuls aim to echo ADARx’s first-day pop: Public Equity Report
BIOCENTURY | FINANCEMORE IPO HOPEFULS AIM TO ECHO ADARX’S FIRST-DAY POP: PUBLIC EQUITY REPORTFilings by City, Iambic, Retension, and TRexBio fatten the queue
-
Capital, M&A & Industry Strategy1 month agoHow reverse merger-plus-PIPE deals came to rival the IPO path to market
BIOCENTURY | FINANCEHOW REVERSE MERGER-PLUS-PIPE DEALS CAME TO RIVAL THE IPO PATH TO MARKETTighter control over syndicates, timing advantages offer an alternative that’s no longer an...
-
Capital, M&A & Industry Strategy1 month ago
PIPEs power new wave of reverse mergers
BIOCENTURY | FINANCEPIPES POWER NEW WAVE OF REVERSE MERGERSAfter a five-year decline in companies merging to go public, reverse merger-plus-PIPE deals are on the rise in...
-
AI, Machine Learning & Computational Biology1 month agoNetwork Bio: Building disease-specific AI models with biobank data
BIOCENTURY | EMERGING COMPANY PROFILENETWORK BIO: BUILDING DISEASE-SPECIFIC AI MODELS WITH BIOBANK DATAPalo Alto-based biotech identifying ‘barcodes’ from patient-derived tissues to model diseases over time for...
-
Capital, M&A & Industry Strategy1 month agoEnveda’s latest megaround puts $311M behind AI push: Venture Report
BIOCENTURY | FINANCEENVEDA’S LATEST MEGAROUND PUTS $311M BEHIND AI PUSH: VENTURE REPORTPlus: Basecamp readies for its next climb with $140M round; Finland’s Kasvu draws €30M for antidepressant;...
-
Regulatory Intelligence & Drug Approvals1 month agoOverton vows speed, deference to staff reviews, if confirmed to lead FDA
BIOCENTURY | POLITICS, POLICY & LAWOVERTON VOWS SPEED, DEFERENCE TO STAFF REVIEWS, IF CONFIRMED TO LEAD FDAThe commissioner nominee faced sharp questions about vaccines, abortion drugs,...
-
Global Biotechnology & Pharmaceutical Markets1 month agoHow Europe’s VCs are chasing NewCo deals in China
BIOCENTURY | FINANCEHOW EUROPE’S VCS ARE CHASING NEWCO DEALS IN CHINAAs European investors court Chinese biotechs for assets, deal terms — from equity stakes to IPO...
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoScience Spotlight: Degrading proteins without ubiquitin
BIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: DEGRADING PROTEINS WITHOUT UBIQUITINBioCentury’s roundup of translational innovations also includes menopause proteomics and an mRNA-encoded T cell engager
-
Capital, M&A & Industry Strategy1 month agoLed by the U.S. and China, radiopharma financing reaches new heights
BIOCENTURY | DATA BYTELED BY THE U.S. AND CHINA, RADIOPHARMA FINANCING REACHES NEW HEIGHTSTelix debt places Australia among leaders
Widespread atropine use fails to sway FDA advisors on Sydnexis data
At least 11 PDUFAs on FDA’s November docket
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
